IN2014DN08011A - - Google Patents

Info

Publication number
IN2014DN08011A
IN2014DN08011A IN8011DEN2014A IN2014DN08011A IN 2014DN08011 A IN2014DN08011 A IN 2014DN08011A IN 8011DEN2014 A IN8011DEN2014 A IN 8011DEN2014A IN 2014DN08011 A IN2014DN08011 A IN 2014DN08011A
Authority
IN
India
Prior art keywords
mmp9
functional fragment
binding proteins
gelatinase
immunoglobulin
Prior art date
Application number
Inventor
Victoria Smith
Scott Mccauley
Original Assignee
Gilead Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Biologics Inc filed Critical Gilead Biologics Inc
Publication of IN2014DN08011A publication Critical patent/IN2014DN08011A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24035—Gelatinase B (3.4.24.35), i.e. matrix metalloprotease 9 or MMP9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
    • G01N2333/96494—Matrix metalloproteases, e. g. 3.4.24.7

Abstract

The present disclosure provides compositions and methods of use involving binding proteins e.g. antibodies and antigen binding fragments thereof that bind to the matrix metalloproteinase 9 (MMP9) protein (MMP9 is also known as gelatinase B) such as where the binding proteins comprise an immunoglobulin (Ig) heavy chain (or functional fragment thereof) and an Ig light chain (or functional fragment thereof).
IN8011DEN2014 2012-02-29 2012-02-29 IN2014DN08011A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2012/027160 WO2013130078A1 (en) 2012-02-29 2012-02-29 Antibodies to matrix metalloproteinase 9

Publications (1)

Publication Number Publication Date
IN2014DN08011A true IN2014DN08011A (en) 2015-05-01

Family

ID=45816000

Family Applications (1)

Application Number Title Priority Date Filing Date
IN8011DEN2014 IN2014DN08011A (en) 2012-02-29 2012-02-29

Country Status (23)

Country Link
US (4) US9550836B2 (en)
EP (1) EP2820048B1 (en)
JP (1) JP6067756B2 (en)
KR (1) KR20140130724A (en)
CN (1) CN104395345A (en)
AP (1) AP2014007907A0 (en)
AU (4) AU2012318302C1 (en)
BR (1) BR112014021477A2 (en)
CA (1) CA2865530C (en)
CL (1) CL2014002282A1 (en)
CO (1) CO7061040A2 (en)
CR (1) CR20140443A (en)
EA (1) EA201491575A1 (en)
EC (1) ECSP14020504A (en)
ES (1) ES2731441T3 (en)
HK (2) HK1205153A1 (en)
IN (1) IN2014DN08011A (en)
MD (1) MD20140107A2 (en)
MX (1) MX2014010449A (en)
PH (1) PH12014501931A1 (en)
SG (1) SG11201405305PA (en)
WO (1) WO2013130078A1 (en)
ZA (1) ZA201406319B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ701444A (en) 2010-08-27 2016-06-24 Gilead Biologics Inc Antibodies to matrix metalloproteinase 9
EP3255063A3 (en) * 2012-02-29 2018-02-07 Gilead Biologics, Inc. Antibodies to matrix metalloproteinase 9
SG11201405305PA (en) 2012-02-29 2014-09-26 Gilead Biologics Inc Antibodies to matrix metalloproteinase 9
MX2016011177A (en) * 2014-02-27 2016-12-16 Gilead Sciences Inc Antibodies to matrix metalloproteinase 9 and methods of use thereof.
EP2985295A1 (en) * 2014-08-13 2016-02-17 Calypso Biotech SA Antibodies specific for MMP9
EP2985296A1 (en) 2014-08-13 2016-02-17 Calypso Biotech SA Antibodies specific for MMP9
CN105037553B (en) * 2015-08-20 2018-04-17 内蒙古蒙元生物基因科技有限公司 A kind of immunoglobulin that can detect cancer
US20170306050A1 (en) 2016-04-08 2017-10-26 Gilead Sciences, Inc. Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
US10326830B1 (en) * 2016-09-02 2019-06-18 Amazon Technologies, Inc. Multipath tunneling to a service offered at several datacenters
JP7141397B2 (en) 2016-12-16 2022-09-22 ユニヴェルシテ・ドゥ・ボルドー MMP9 inhibitors and their use in the prevention or treatment of depigmentation disorders
WO2018170488A1 (en) 2017-03-17 2018-09-20 Gilead Sciences, Inc. Method of purifying an antibody
WO2019017338A1 (en) 2017-07-18 2019-01-24 第一三共株式会社 Active mmp9-binding peptide
CN110885375B (en) * 2019-12-20 2021-07-02 南京融捷康生物科技有限公司 Single-domain antibody specifically aiming at MMP-9 protein zinc ion binding domain, product and application
CN111785321B (en) * 2020-06-12 2022-04-05 浙江工业大学 DNA binding residue prediction method based on deep convolutional neural network
CN117327186B (en) * 2023-07-12 2024-03-12 北京达成生物科技有限公司 Bispecific antibodies that bind MMP3 proteins and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP0546073B1 (en) 1990-08-29 1997-09-10 GenPharm International, Inc. production and use of transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
GB9022788D0 (en) 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
DE69233528T2 (en) 1991-11-25 2006-03-16 Enzon, Inc. Process for the preparation of multivalent antigen-binding proteins
EP1203025B1 (en) * 1999-07-13 2009-07-01 University Of Southern California Novel method and composition for inhibition of angiogenesis using antagonists based on mmp-9 and beta1 integrins
CN1459505A (en) * 2002-05-21 2003-12-03 赵平 Chinese Han nationality people stroma metallopankrin-9 gene reconstitution, expression, purification and its medical application
CA2496834C (en) * 2002-09-06 2014-03-18 Alexion Pharmaceuticals, Inc. Method of treatment of asthma using antibodies to complement component c5
RU2470941C2 (en) * 2005-12-02 2012-12-27 Дженентек, Инк. Binding polypeptides and use thereof
WO2008154439A1 (en) * 2007-06-08 2008-12-18 Irm Llc Methods and compositions for inducing apoptosis in cancer cells
US8008445B2 (en) * 2008-03-03 2011-08-30 Dyax Corp. Metalloproteinase 9 binding proteins
JP2011517320A (en) * 2008-03-03 2011-06-02 ダイアックス コーポレーション Metalloprotease 9 binding protein and metalloprotease 2 binding protein
WO2010048432A1 (en) * 2008-10-22 2010-04-29 Dyax Corp. Combination treatments comprising protease binding proteins for inflammatory disorders
US20110286916A1 (en) * 2008-11-20 2011-11-24 Jose Miguel Aste-Amezaga Generation and characterization of anti-notch antibodies for therapeutic and diagnostic use
US8697078B2 (en) * 2010-01-27 2014-04-15 Yeda Research And Development Co. Ltd. Antibodies that inhibit metalloproteins
NZ701444A (en) 2010-08-27 2016-06-24 Gilead Biologics Inc Antibodies to matrix metalloproteinase 9
EP3255063A3 (en) 2012-02-29 2018-02-07 Gilead Biologics, Inc. Antibodies to matrix metalloproteinase 9
SG11201405305PA (en) 2012-02-29 2014-09-26 Gilead Biologics Inc Antibodies to matrix metalloproteinase 9

Also Published As

Publication number Publication date
AU2012318302C1 (en) 2017-06-15
US20190127486A1 (en) 2019-05-02
CN104395345A (en) 2015-03-04
AU2015242967B2 (en) 2017-08-24
ZA201406319B (en) 2016-02-24
AP2014007907A0 (en) 2014-08-31
US20170183421A1 (en) 2017-06-29
AU2017261626A1 (en) 2017-12-07
HK1205153A1 (en) 2015-12-11
AU2017216508A1 (en) 2017-08-31
AU2012318302B2 (en) 2016-08-18
AU2015242967A1 (en) 2015-11-05
AU2012318302A1 (en) 2013-09-19
WO2013130078A1 (en) 2013-09-06
HK1208036A1 (en) 2016-02-19
CR20140443A (en) 2014-11-17
JP2015514394A (en) 2015-05-21
ES2731441T3 (en) 2019-11-15
CA2865530C (en) 2019-02-19
CL2014002282A1 (en) 2015-02-20
US20150140580A1 (en) 2015-05-21
EP2820048A1 (en) 2015-01-07
AU2017216508B2 (en) 2019-03-07
US20210054101A1 (en) 2021-02-25
MX2014010449A (en) 2015-02-10
EA201491575A1 (en) 2015-01-30
CO7061040A2 (en) 2014-09-19
ECSP14020504A (en) 2015-09-30
NZ629888A (en) 2017-02-24
PH12014501931A1 (en) 2014-11-24
JP6067756B2 (en) 2017-01-25
US11634505B2 (en) 2023-04-25
US10800857B2 (en) 2020-10-13
KR20140130724A (en) 2014-11-11
MD20140107A2 (en) 2015-03-31
SG11201405305PA (en) 2014-09-26
BR112014021477A2 (en) 2018-06-12
CA2865530A1 (en) 2013-09-06
US9550836B2 (en) 2017-01-24
EP2820048B1 (en) 2019-04-17

Similar Documents

Publication Publication Date Title
PH12016501691A1 (en) Antibodies to matrix metalloproteinase 9
MX2018007630A (en) Antibodies to matrix metalloproteinase 9.
IN2014DN08011A (en)
EA201791961A1 (en) ANTIBODIES SPECIFIC TO CD47 AND PD-L1
PH12014502527B1 (en) St2 antigen binding proteins
EA201591153A1 (en) ANTIBODIES CONNECTING TL1A AND THEIR APPLICATION
EA201591091A1 (en) Antigen-binding proteins for BCMA
IN2014DN03451A (en)
EA201491214A1 (en) COMPOSITIONS AND METHODS OF APPLICATION OF ANTIBODIES AIMED AT THE FACTOR P
EA201492101A1 (en) ANTIBODIES AGAINST FCRN
ES2639026T3 (en) Totally human antibodies specific for CADM1
EA201291065A1 (en) ANTIBODIES AGAINST VLA-4
CY1123519T1 (en) HUMAN IL-ẞ NEUTRALIZING MONOCLONAL ANTIBODIES
EA201491724A1 (en) ANTIBODIES, NEUTRALIZING RSV, MPV AND PVM, AND THEIR APPLICATIONS
MX2016011177A (en) Antibodies to matrix metalloproteinase 9 and methods of use thereof.
EA201792576A1 (en) ANTIBODIES, NEUTRALIZING RSV, MPV AND PVM, AND THEIR APPLICATIONS
CL2010000521A1 (en) Isolated antibody or fragment that blocks the binding of the protein binding wise; cdr sequences of the light and heavy chain; immunogenic polypeptide of wise; pharmaceutical composition comprising said antibody.